Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie Inc. on Thursday reported second-quarter sales and profit that beat expectations as newer immunology drugs delivered the rapid growth needed to offset plunging sales of blockbuster Humira.

AbbVie's quarterly results top estimates as newer drugs cushion Humira's slide

Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $0.52 Per Share Related to Acquired IPR&D and Milestones Expense    Delivers Second-Quarter Net Revenues of $14.462 Billion, an Increase of 4.3 Percent on a Reported Basis and 5.6 Percent on an Operational Basis    Second -Quarter Global Net Revenues from the Immunology Portfolio Were $6.971 Billion, an Increase of 2.3 Percent on a Reported Basis, or 3.5 Percent on an Operational Basis; Global Humira Net Revenues Were $2.814 Billion; Global Skyrizi Net Revenues Were $2.727 Billion; Global Rinvoq Net Revenues Were $1.430 Billion   Second -Quarter Global Net Revenues from the Oncology Portfolio Were $1.634 Billion, an Increase of 10.5 Percent on a Reported Basis, or 12.2 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $833 Million; Global Venclexta Net Revenues Were $637 Million   Second -Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.162 Billion, an Increase of 14.7 Percent on a Reported Basis, or 15.2 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $814 Million; Global Vraylar Net Revenues Were $774 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $381 Million   Second -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.390 Billion, an Increase of 0.5 Percent on a Reported Basis, or 2.8 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $729 Million; Global Juvederm Net Revenues Were $343 Million   Raises 2024 Adjusted Diluted EPS Guidance Range from $10.61 - $10.81 to $10.71 - $10.91, which Includes an Unfavorable Impact of $0.60 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2024 NORTH CHICAGO, Ill. , July 25, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2024.

AbbVie Reports Second-Quarter 2024 Financial Results

Broadcom

Home Depot

Iron Mountain

Realty Income Corp

Procter & Gamble

Williams

Arguably, there's never a bad time to consider trustworthy dividend stocks. By securing passive income, you can complement any returns you generate through speculation.

7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio

Apple

AGNC Investment

Antero Midstream Partners

Apple Hospitality REIT

Ares Capital

Apollo Commercial Real Estate Finance

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Bank of Montreal

Bayerische Motoren Werke AG

Bank of Nova Scotia

BRT Apartments

Blackstone Group

Blackstone Secured Lending Fund

Colgate-Palmolive

Canadian Imperial Bank of Commerce

Investment activity remained high in June, focusing on BDCs aiming to increase dividend income by at least $100 each month. Adjusted dividend income in June is up 27% Y/Y and 5% vs the previous quarter. Main portfolio picks included Ares Capital, Hercules Capital, Goldman Sachs BDC, and MidCap Financial Investment Corporation.

My Dividend Stock Portfolio: New June Dividend Record - 101 Holdings With 22 Buys

BOSTON and SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation (“Frontier” or the “Company”), a clinical-stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced the advancement of lead candidates for further optimization in an AbbVie partnered program targeting a key transcription factor for cancer cell survival, triggering an accompanying milestone payment.

Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.

AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?

AbbVie's lead drug, Humira, lost patent-protected market exclusivity in 2023, but sales have been relatively resilient to new competition. Despite losing billions in Humira revenue, total sales are still on the rise.

AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?

Abbott Labs

Amgen

Lowe's

Nordson

NIKE

Parker-Hannifin

S&P Global

Target

Visa

These blue-chip companies have demonstrated strong dividend growth rates ranging from 7.69% to 15.8% annually over the past five years. The list includes diverse sectors such as retail, healthcare, technology, and finance, offering potential for portfolio diversification.

10 Best Dividend Growth Stocks to Buy and Hold Forever

AbbVie (ABBV) closed at $172.32 in the latest trading session, marking a +0.69% move from the prior day.

AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts

We recently sold our ABBV shares at $175. The stock has reached our target valuation at this price. More fundamentally, we think the market has corrected its overreaction to the Humira patent cliff by now.

AbbVie: Why I Sold My Shares At $175

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AbbVie (ABBV) Q2 Earnings Expected to Decline

AbbVie Inc. will announce its Q2 2024 earnings next Thursday, 25th July. The company has a new CEO, with insider Rob Michael taking the reins after long-term CEO Rick Gonzalez's retirement. Wall Street watches Humira's revenue post patent expiry in the US closely, and sold stock after Q1 showed a >30% YOY decline.

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

Healthpeak Properties Inc

LyondellBasell Industries

PepsiCo

Philip Morris

Shell PLC

Vici Properties

While active acquisition is perhaps the most common methodology of gaining wealth, it's not always the most efficient. For example, even if you trade your hours for a generous paycheck, there are only so many hours available: in a day, in a week, in a month, you get the idea.

7 High-Yield Dividend Stocks to Help Pay Your Bills

PayPal

Verizon

Drugmaker AbbVie has been investing in its growth, and that strategy looks to be paying off. Verizon's stable business and low valuation make it practically a no-brainer buy for dividend investors.

3 Absurdly Cheap Stocks to Buy and Hold for Years

Cisco Systems

Diamondback Energy

Medtronic

Nokia

Pfizer

At this writing, current inflation rate is 3% over the past 12 months. That's the reading as of the end of June.

7 High-Yield Dividend Stocks Beating Inflation

Costco

Dollar General

Coca-Cola

NextEra Energy

Southern Company

Walmart

U.S. News & World Report recently said the New York Fed's Recession Probability model hints that within the next 12 months, we stand a 55.8% chance of a recession. One can never be too safe though.

7 Recession-Proof Stocks to Shield Your Portfolio in 2024

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.

AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU

Gilead Sciences

AbbVie is poised to keep a 52-year streak of dividend hikes going. Amgen offers more than a dividend with its promising pipeline.

3 Dividend Growth Stocks to Buy and Hold

News for AbbVie Stock (ABBV)